BACKGROUND: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma.
METHODS: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review.
CONCLUSION: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.
Written by:
Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Are you the author?
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States; Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
Reference: Cancer Lett. 2014 Feb 28;343(2):156-60.
doi: 10.1016/j.canlet.2013.09.038
PubMed Abstract
PMID: 24239667
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Renal Cancer Section
